Literature DB >> 22341684

HPLC quantification of doxorubicin in plasma and tissues of rats treated with doxorubicin loaded poly(alkylcyanoacrylate) nanoparticles.

Khairallah Alhareth1, Christine Vauthier, Claire Gueutin, Gilles Ponchel, Fathi Moussa.   

Abstract

The long-term clinical use of doxorubicin (Dox), one of the most important anticancer agent in use, is limited by dose-related acute cardiotoxicity, myelo-suppression and multidrug resistance developed by cancer cells. To improve the antitumor efficacy and reduce the toxicity of Dox, many drug delivery systems have been developed, including poly(alkylcyanoacrylate) (PACA) nanoparticles. A new formulation of PACA nanoparticles with potential stealth properties were prepared by redox radical emulsion polymerization and associated to Dox in our laboratory. To comparatively investigate the pharmacokinetics and the biodistribution of different formulations of Dox associated PACA nanoparticles, a simple and rapid high performance liquid chromatographic method (HPLC) was developed for the quantification of Dox in plasma and tissues of rats treated with Dox loaded PACA nanoparticle (Dox-PACA). Dox was eluted at 4.4 min and it was well separated from its main metabolites doxorubicinol (Doxl) and doxorubicinon (Doxon) and idarubicin (Ida) used as internal standard (IS). Extraction of Dox from biological media was achieved by liquid-liquid extraction. The recovery of total Dox (i.e. free Dox and Dox associated with nanoparticles) from plasma and tissues (liver, spleen and heart) spiked with Dox-PACA were 71 and 78% for 0.05 and 1 μg/mL in rat plasma, respectively, and 73% and 80% for 0.5 and 10 μg/g in tissues, respectively. The method is linear from 0.05 to 1.5 μg/mL of Dox in plasma. The limit of detection of the method is 0.5 ng of Dox per injection (50 μL). The between-day and within-day precisions of the method were 97.1-102.9% and 97.3-101.7% for concentrations ranging from 0.05 to 1 μg/mL, respectively. Preliminary data suggested that this method can be applied to determine the pharmacokinetic and biodistribution of Dox associated with PACA nanoparticles after intravenous administration to rats. Copyright Â
© 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22341684     DOI: 10.1016/j.jchromb.2012.01.025

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  12 in total

1.  Evaluation of antitumor activity and cardiac toxicity of a bone-targeted ph-sensitive liposomal formulation in a bone metastasis tumor model in mice.

Authors:  Diego Dos Santos Ferreira; Bruno Luís Jesus de Oliveira Pinto; Vidhya Kumar; Valbert Nascimento Cardoso; Simone Odília Fernandes; Cristina Maria Souza; Geovanni Dantas Cassali; Anna Moore; David E Sosnovik; Christian T Farrar; Elaine Amaral Leite; Ricardo José Alves; Mônica Cristina de Oliveira; Alexander Ramos Guimarães; Peter Caravan
Journal:  Nanomedicine       Date:  2017-03-23       Impact factor: 5.307

2.  An injectable nanoparticle generator enhances delivery of cancer therapeutics.

Authors:  Rong Xu; Guodong Zhang; Junhua Mai; Xiaoyong Deng; Victor Segura-Ibarra; Suhong Wu; Jianliang Shen; Haoran Liu; Zhenhua Hu; Lingxiao Chen; Yi Huang; Eugene Koay; Yu Huang; Jun Liu; Joe E Ensor; Elvin Blanco; Xuewu Liu; Mauro Ferrari; Haifa Shen
Journal:  Nat Biotechnol       Date:  2016-03-14       Impact factor: 54.908

3.  Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice.

Authors:  Rui Xue Zhang; Tian Zhang; King Chen; Ji Cheng; Paris Lai; Andrew M Rauth; K Sandy Pang; Xiao Yu Wu
Journal:  J Vis Exp       Date:  2017-10-05       Impact factor: 1.355

4.  Spatial mapping of drug delivery to brain tissue using hyperspectral spatial frequency-domain imaging.

Authors:  Rajinder P Singh-Moon; Darren M Roblyer; Irving J Bigio; Shailendra Joshi
Journal:  J Biomed Opt       Date:  2014-09       Impact factor: 3.170

5.  A Simple and Sensitive HPLC Method for Fluorescence Quantitation of Doxorubicin in Micro-volume Plasma: Applications to Pharmacokinetic Studies in Rats.

Authors:  Marjan Daeihamed; Azadeh Haeri; Simin Dadashzadeh
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

6.  Deposition of doxorubicin in rats following administration of three newly synthesized doxorubicin conjugates.

Authors:  Menglei Huan; Shuang Tian; Han Cui; Bangle Zhang; Dan Su; Jieping Wang; Kangchu Li; Weidong Cao
Journal:  Biomed Res Int       Date:  2013-12-05       Impact factor: 3.411

7.  HPLC Method Development for Quantification of Doxorubicin in Cell Culture and Placental Perfusion Media.

Authors:  Mansi Shah; Luke Bourner; Shariq Ali; Sanaalarab Al-Enazy; Menatallah M Youssef; Morgan Fisler; Erik Rytting
Journal:  Separations       Date:  2018-01-24

8.  Fabrication of an electrochemical sensor for determination of doxorubicin in human plasma and its interaction with DNA.

Authors:  Reza Hajian; Zahra Tayebi; Nafiseh Shams
Journal:  J Pharm Anal       Date:  2016-07-19

Review 9.  Alterations in Cellular Processes Involving Vesicular Trafficking and Implications in Drug Delivery.

Authors:  Silvia Muro
Journal:  Biomimetics (Basel)       Date:  2018-07-24

10.  Heparan sulfate targeting strategy for enhancing liposomal drug accumulation and facilitating deep distribution in tumors.

Authors:  Ping-Hsueh Kuo; Yi-Hsien Teng; Ann-Lun Cin; Wen Han; Pei-Wan Huang; Lily Hui-Ching Wang; Yu-Ting Chou; Jia-Ling Yang; Yun-Long Tseng; Minhsiung Kao; Margaret Dah-Tsyr Chang
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.